386 related articles for article (PubMed ID: 3137401)
21. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
22. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
[No Abstract] [Full Text] [Related]
23. "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up.
Kyle RA
Mayo Clin Proc; 1993 Jan; 68(1):26-36. PubMed ID: 8417251
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.
Grunenberg A; Buske C
Dtsch Arztebl Int; 2017 Nov; 114(44):745-751. PubMed ID: 29169431
[TBL] [Abstract][Full Text] [Related]
25. [Skin disorders associated with monoclonal gammopathies].
Houtman CJ; Genders RE; von dem Borne PA; Vermeer MH
Ned Tijdschr Geneeskd; 2014; 158():A6717. PubMed ID: 24780569
[TBL] [Abstract][Full Text] [Related]
26. [Monoclonal gammopathy of undetermined significance : when and why to look for them ?].
Meuleman N; Vercruyssen M
Rev Med Brux; 2018; 39(4):302-306. PubMed ID: 30320992
[TBL] [Abstract][Full Text] [Related]
27. Protein self-organization patterns in dried serum reveal changes in B-cell disorders.
Killeen AA; Ossina N; McGlennen RC; Minnerath S; Borgos J; Alexandrov V; Sarvazyan A
Mol Diagn Ther; 2006; 10(6):371-80. PubMed ID: 17154654
[TBL] [Abstract][Full Text] [Related]
28. AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of "monoclonal gammopathy of inflammatory significance"?
Terré A; Colombat M; Cez A; Martin C; Diet C; Brechignac S; Oghina S; Bodez D; Faguer S; Savey L; Galland J; Boffa JJ; Grateau G; Jaccard A; Buob D; Georgin-Lavialle S
Int J Clin Pract; 2021 Nov; 75(11):e14817. PubMed ID: 34490695
[TBL] [Abstract][Full Text] [Related]
29. [Monoclonal gammopathies of undetermined significance called "MGUS"].
Clément F
Schweiz Med Wochenschr; 1989 Jul; 119(27-28):970-8. PubMed ID: 2508215
[TBL] [Abstract][Full Text] [Related]
30. [Current status regarding detection of monoclonal component in Japan].
Yamada T
Rinsho Byori; 2010 Apr; 58(4):397-400. PubMed ID: 20496769
[TBL] [Abstract][Full Text] [Related]
31. Does my patient with a serum monoclonal spike have multiple myeloma?
Bianchi G; Ghobrial IM
Hematol Oncol Clin North Am; 2012 Apr; 26(2):383-93, ix. PubMed ID: 22463833
[TBL] [Abstract][Full Text] [Related]
32. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese.
Lee LN; Jan IS; Tien HF; Lin JS; Lo SC; Cheng WC
J Formos Med Assoc; 2002 Feb; 101(2):91-7. PubMed ID: 12099210
[TBL] [Abstract][Full Text] [Related]
33. [Study of monoclonal gammopathy in Kagawa Prefectural Central Hospital].
Uchida M; Taida N; Kanao M; Kagamihara H; Kuwajima M
Rinsho Byori; 2004 Jul; 52(7):574-9. PubMed ID: 15344556
[TBL] [Abstract][Full Text] [Related]
34. Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Fend F; Dogan A; Cook JR
Virchows Arch; 2023 Jan; 482(1):163-177. PubMed ID: 36414803
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal gammopathies of undetermined significance: a review.
Kyle RA; Rajkumar SV
Immunol Rev; 2003 Aug; 194():112-39. PubMed ID: 12846812
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal gammopathy of undetermined significance.
Kyle RA
Blood Rev; 1994 Sep; 8(3):135-41. PubMed ID: 7819815
[TBL] [Abstract][Full Text] [Related]
37. Screening for and diagnosis of monoclonal gammopathy.
Chong YP; Lim SM; Loh TP; Mollee P; Wijeratne N; Choy KW
J Clin Pathol; 2023 Nov; 76(11):727-733. PubMed ID: 37604683
[TBL] [Abstract][Full Text] [Related]
38. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
Kyle RA; Therneau TM; Rajkumar SV; Remstein ED; Offord JR; Larson DR; Plevak MF; Melton LJ
Blood; 2003 Nov; 102(10):3759-64. PubMed ID: 12881316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
